The sad news of the death of Professor Mike Cawthorne, PhD, was announced in July 2015.
As leader of the team at SmithKline Beecham, now GlaxoSmithKline, which developed the thiazolidinedione insulin-sensitizing drug rosiglitazone, Mike was at the interface of metabolism and cardiovascular disease.
In recent years, Mike directed the internationally recognized Institute for Translational Medicine based in the Clore Laboratory at the University of Buckingham, UK. He served as dean of postgraduate medicine and science and was deputy vice-chancellor of the university. Mike was also a driving force behind the creation of the UK’s newest undergraduate medical school at the University of Buckingham and its associated teaching hospital in Milton Keynes.
I consider myself fortunate to have known Mike on a personal level. Our stimulating discussions on diabetes pharmacotherapy and the future direction of diabetes research were always stimulating. Mike was warm, thoughtful and inquisitive and possessed of a rare and contagious energy.
An appreciation of Mike’s life can be found at: http://www.buckingham.ac.uk/latest-news/michael-anthony-cawthorne-1941-2015/
Andrew J. Krentz Profil Institute for Clinical Research Inc., Chula Vista, California, USA